Please assess the completion status of the following clinical trial:

Trial Title: Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* patients in the high-risk population of ESCC;~* or general risk population of ESCC between 40 to 74 years old. Definition of high-risk population of ESCC is list in supporting information33.~Exclusion criteria included the following:~* with obvious abnormalities in stomach, confirmed by either white-light endoscopy (WLE) or pCLE, including gastric cancer, acute erosive and hemorrhagic gastritis, chronic atrophic gastritis, H. pylori infection and severe bile reflux gastritis;~* advanced esophageal carcinoma;~* known esophageal surgery or endoscopic treatment;~* known esophageal radiotherapy or chemotherapy;~* esophageal stenosis;~* food retention;~* allergy to iodine or fluorescein sodium;~* hyperthyroid;~* coagulopathy;~* acute bleeding;~* severe organ failure;~* pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- 1.2% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
- 1.0% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
- 0.8% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
- 0.6% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
- 0.4% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).